Tirzepatide Trial Demonstrates SubstantialWeight Loss

被引：2
|
作者：
不详
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2022年 / 328卷 / 04期
关键词：
D O I：
10.1001/jama.2022.11895
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：322 / 322
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The Surpass Clinical Trial Program
    Barros, Mike
    Levine, Joshua A.
    AMERICAN HEART JOURNAL, 2022, 254 : 241 - 242
  • [22] The effectiveness and sustainability of health outcomes from a holistic digital weight-loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK
    Talay, Louis
    Vickers, Matt
    Alvi, Omar
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 4854 - 4863
  • [23] Morphometry demonstrates loss of cortical thickness in cerebral microangiopathy
    C. Preul
    G. Lohmann
    M. Hund–Georgiadis
    T. Guthke
    D. Y. von Cramon
    Journal of Neurology, 2005, 252 : 441 - 447
  • [24] Efficacy and Safety of Tirzepatide in Type 2 Diabetes: The SURPASS Clinical Trial Program
    Finney, Denis
    Levine, Josh A.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 142 : S20 - S20
  • [25] Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial
    Packer, Milton
    CIRCULATION, 2024, 150 (25) : E714 - E714
  • [26] Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
    Mark A. Moyad
    Current Urology Reports, 2023, 24 : 515 - 525
  • [27] Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
    Moyad, Mark A.
    CURRENT UROLOGY REPORTS, 2023, 24 (11) : 515 - 525
  • [28] SPIRONOLACTONE FOR HIRSUTISM - A CONTROLLED TRIAL DEMONSTRATES NO OBJECTIVE BENEFIT
    RENTOUL, J
    MCLELLAN, AR
    MACKIE, R
    MCINNES, GT
    JOURNAL OF ENDOCRINOLOGY, 1987, 112 : 169 - 169
  • [29] The Jena trial demonstrates the benefits of floristic diversity to pastures
    Fischer, M.
    Rottstock, T.
    Marquard, E.
    Middelhoff, C.
    Roscher, C.
    Temperton, V. -M.
    Oelmann, Y.
    Weigelt, A.
    FOURRAGES, 2008, (195): : 275 - 286
  • [30] Tirzepatide versus insulin lispro in type 2 diabetes: SURPASS-6 trial
    Clauss, R. Maria
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (01) : 26 - 26
12345